Cervical Cancer ScreeningOptiTri_GCNCT07177170
Impact of a Single Versus Multiple Visits on the Cervical Cancer Screening Completeness, Feasibility and Acceptability Among Women Living With HIV in Cameroon
A study testing Differentiated screening delivery and Single visit in people with Cervical Cancer Screening and HIV, run by Institut de Recherche pour le Developpement at 1 site in Cameroon.
Trial summary
Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. Read more about this study
- Who is it for?
- Ages 25 to 49 years, women only
- Conditions the study is for
- Cervical Cancer Screening, HIV
- What is being tested?
- Differentiated screening delivery and Single visit
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,422 participants
- Where
- 1 siteCameroon
- Study dates
- 12 Dec 2024to May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 49 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- HIV infection
- receiving antiretroviral therapy
- living in the department of the study hospital
Who cannot join
- ongoing pregnancy
- hysterectomy
- treatment of cervical lesion in the past 12 months
- Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.);
- Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study Inclusion deferred if
- menstrual bleeding
- post-partum (<12 weeks after delivery)
- clinicla signs of cervical or pelvic infection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Cameroon1 site, 1 recruiting
- Recruiting
Foumban hospital
Foumban
Amadou NJIFOU NJIMAH, Prof, +227679161300, cdpoptitri@gmail.com
About this study
Official title: Optimizing Cervical Cancer Screening Strategies With HPV Testing Among Women Living With HIV in Cameroon: Feasibility, Acceptability, and Impact of a Single-visit Test and Treat Approach in a Hospital Center With an HPV Testing Platform
Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required.
Dropout may occur at these different steps, compromising the success of the CC elimination strategy. Performing the all screening and treatment sequence in a single visit has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are performed in multiple visites for logistical reasons, resulting in many dropouts. Strategies based on the differentiated prestation approaches, which propose a simplified management centered on the patients preferences, could guide the adaptation of the single-visit approach to account for contextual constraints while maintaining high effectiveness.
Read more
The OptiTri-GC study aims to design and assess the impact of a differentiated CC screen and treat strategy in a district hospital; It will assess both its implementation and its effectiveness based on the completeness at each stage of the screening cascade. In addition, it will also include three sub-studies designed to evaluate :
- The performance of urinary HPV testing.
- The performance of different methods to identify women requiring a treatment.
- The risk of post-treatment cervical disease.
This study has two periods. During the first period, a single visit approach will be used while differentiated approach will be prepared using participatory research. During the second period, the differentiated approach will be implemented. The screening overall completeness will be compared between the two periods to assess the differentiated approach effectiveness.
The study will also assess the implementation of each screening strategy in terms of :
- Success through the measure of fidelity, reach and completeness
- Identification of adaptation, barriers and facilitating/leverage factors
- Perception, feasibility and acceptability of the screening strategies (by patients and health care workers) It will assess the participants' stress levels during the screening process and to identify potential psychosocial support strategies and document the experience of WLHIV and health workers during the screening process and the post-treatment follow-up.
Other study objectives include :
- To assess the performance of different methods to identify women requiring a treatment
- To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples
- To assess the efficacy of treatment in terms of post-treatment cervical lesions
Methodology. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative.
Read the detailed description
Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. There is compelling evidence that screening for human papillomavirus (HPV) infection by testing is a very sensitive method for identifying women at risk for precancerous lesions of the cervix. But since HPV infections are very common among WLHIV, it is necessary to have secondary triage to identify women who need to be treated.
The HPV-based screening approach includes multiple steps, and dropout may occur at these different steps, compromising the success of the CC elimination strategy. A single-visit screen and treat approach has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are often performed in multiple visites for logistical reasons, resulting in many dropouts. Strategies based on the differentiated prestation approach, which propose a simplified management centered on the patients preferences, could guide the adaptation of the single-visit approach to account for contextual constraints while maintaining high effectiveness.
The OptiTri-GC study aims to design and assess the impact of a differentiated CC screen and treat strategy in a district hospital; It will assess both its implementation and its effectiveness based on the completeness at each stage of the screening cascade. In addition, it will also include three sub-studies designed to evaluate :
- the performance of urinary HPV testing.
- the performance of different post-HPV test triage options (partial genotyping, simple or Artifical Intelligence assisted visual inspection, methylation markers)
- the risk of post-treatment cervical disease and the performance of different cure markers.
This will be a type 2 hybrid study that combines intervention research and implementation research. A quasi-experimental design ("before - after") combined with case study will be used for the effectiveness component of the research. During the first period, a single visit approach will be used while differentiated approach will be prepared using participatory research. During the second period, the differentiated approach will be implemented.
The general objective of this research is to assess the (cost-)effectiveness and implementation of different the two screening delivery strategies.
Main specific objectives include:
- To assess the effectiveness of each implementation strategy (in terms of cascade completeness)
- To assess the implementation of each strategy in terms of :
- Success through the measure of fidelity, reach and completeness
- Identification of adaptation, barriers and facilitating/leverage factors
- Perception, feasibility and acceptability of the screening strategies (by patients and health care workers)
- To assess the participants' stress levels during the screening process and to identify potential psychosocial support strategies
- To document the experience of WLHIV and health workers during the screening process and the post-treatment follow-up.
- To assess the performance of different triage methods among HPV+ participants (partial genotyping, simple or aided visual inspection, S5 methylation)
- To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples
- To assess the efficacy of thermal ablation treatment in terms of post-treatment cervical lesions
Methodology. The implementation research will combine quantitative and qualitative methods and will be based on the i-PARHIS model. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative. Biomedical data will be collected prospectively. The implementation data will combine routine monitoring data, cross-sectional surveys, interviews and observations. The analysis will be sequential or convergent depending on the stages of the project.
- Conditions
- Cervical Cancer Screening, HIV
- Being tested
- Differentiated screening delivery, Single visit
- Keywords
- cervical cancer, screening, HIV, differentiated prestation, implementation, resource-limited setting, thermal ablation, HPV test
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Differentiated screening deliveryOther
More flexibility in the screening delivery will be offered. A decision aid process will be implemented to help the participants deciding between the two options.
Single visitOther
All the steps of the screening (using HPV test) and of the treatment will be performed in a single visit (when possible).
| Study group | Role | What they receive |
|---|---|---|
| Single visit | Active comparator | All women will be screened using a single-visit approach Receives: Other: Single visit |
| Differentiated prestation | Experimental | A more flexible screening approach will be offered based on the participants preference. After counseling (following the decision aid approach), participants may decide to performed the screening in two visits. Receives: Other: Differentiated screening delivery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Screening completeness
Proportion of HPV+ participants completing all screening steps within 60 days of inclusion.
Measured: 60 days post screening initiation
Secondary outcomes (5)
Screening completeness 2
Proportion of HPV+ participants completing all screening steps within 120 days of inclusion.
Measured: 120 days post screening initiation
Acceptability of the screening delivery strategy
Questionnaire assessing the acceptability and using a 4 point Likert scale
Measured: Baseline (screening)
Triage performance
Sensitivity, specificity of the triage option to detect CIN2+ and CIN3+ lesion
Measured: Baseline (screening)
Performance of urinary HPV test
Concordance between HPV test results from urine samples and those from cervical specimen collected by the clinician
Measured: Baseline (screeening)
Post treatment cervical lesion
Frequency of CIN2+ lesion 12 months after treatment and performance of the markers of cure (sensitivity and specificity)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2025
- Study start12 Dec 2024
- Primary completionApr 2026 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- Quasi-experimental design ("before - after") combined with a case study
- Masking
- None (open label)
- Enrolment
- 1,422 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut de Recherche pour le Developpement
- Sponsor type
- Other government
- Collaborators
- Ecole Polytechnique Fédérale de Lausanne, Centre Pasteur du Cameroun, Centre Hospitalier Simone VEIL de BEAUVAIS, Institut National de la Santé Et de la Recherche Médicale, France, Queen Mary University of London, Hôpitaux Universitaire de Genève, International Agency for Research on Cancer, Programme PACCI, Abidjan, Côte d'Ivoire, RSD Institute, Cameroon
- Responsible party
- Sponsor
- Investigators
- Pierre Debeaudrap, MD, PhD, Study director, Institut de Recherche pour le Développement (IRD)Joëlle Sobngwi, MD, PhD, Principal investigator, RSD Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07177170
- Sponsor's protocol ID
- IRD_2024_CEPED_OptiTri_GC
- Other IDs
- 22SANIC204, ANRS-0467
- Acronym
- OptiTri_GC
- Status last verified
- Sep 2025
- First submitted
- 22 Aug 2025
- Last updated
- 16 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimizing Cervical Cancer Screening Strategies With HPV Testing Among Women Living With HIV in Cameroon: Feasibility, Acceptability, and Impact of a Single-visit Test and Treat Approach in a Hospital Center With an HPV Testing Platform
- ClinicalTrials.gov ID
- NCT07177170
- Acronym / sponsor ID
- OptiTri_GC / IRD_2024_CEPED_OptiTri_GC
- Conditions
- Cervical Cancer Screening, HIV
- Keywords
- cervical cancer, screening, HIV, differentiated prestation, implementation, resource-limited setting, thermal ablation, HPV test
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,422 participants (estimated)
- Lead sponsor
- Institut de Recherche pour le DeveloppementOther government
- Collaborators
- Ecole Polytechnique Fédérale de Lausanne, Centre Pasteur du Cameroun, Centre Hospitalier Simone VEIL de BEAUVAIS, Institut National de la Santé Et de la Recherche Médicale, France, Queen Mary University of London, Hôpitaux Universitaire de Genève, International Agency for Research on Cancer, Programme PACCI, Abidjan, Côte d'Ivoire, RSD Institute, Cameroon
- Study start
- 12 Dec 2024 (actual)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 16 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required.
Dropout may occur at these different steps, compromising the success of the CC elimination strategy. Performing the all screening and treatment sequence in a single visit has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are performed in multiple visites for logistical reasons, resulting in many dropouts. Strategies based on the differentiated prestation approaches, which propose a simplified management centered on the patients preferences, could guide the adaptation of the single-visit approach to account for contextual constraints while maintaining high effectiveness.
The OptiTri-GC study aims to design and assess the impact of a differentiated CC screen and treat strategy in a district hospital; It will assess both its implementation and its effectiveness based on the completeness at each stage of the screening cascade. In addition, it will also include three sub-studies designed to evaluate :
- The performance of urinary HPV testing.
- The performance of different methods to identify women requiring a treatment.
- The risk of post-treatment cervical disease.
This study has two periods. During the first period, a single visit approach will be used while differentiated approach will be prepared using participatory research. During the second period, the differentiated approach will be implemented. The screening overall completeness will be compared between the two periods to assess the differentiated approach effectiveness.
The study will also assess the implementation of each screening strategy in terms of :
- Success through the measure of fidelity, reach and completeness
- Identification of adaptation, barriers and facilitating/leverage factors
- Perception, feasibility and acceptability of the screening strategies (by patients and health care workers) It will assess the participants' stress levels during the screening process and to identify potential psychosocial support strategies and document the experience of WLHIV and health workers during the screening process and the post-treatment follow-up.
Other study objectives include :
- To assess the performance of different methods to identify women requiring a treatment
- To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples
- To assess the efficacy of treatment in terms of post-treatment cervical lesions
Methodology. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative.
Detailed description
Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. There is compelling evidence that screening for human papillomavirus (HPV) infection by testing is a very sensitive method for identifying women at risk for precancerous lesions of the cervix. But since HPV infections are very common among WLHIV, it is necessary to have secondary triage to identify women who need to be treated.
The HPV-based screening approach includes multiple steps, and dropout may occur at these different steps, compromising the success of the CC elimination strategy. A single-visit screen and treat approach has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are often performed in multiple visites for logistical reasons, resulting in many dropouts. Strategies based on the differentiated prestation approach, which propose a simplified management centered on the patients preferences, could guide the adaptation of the single-visit approach to account for contextual constraints while maintaining high effectiveness.
The OptiTri-GC study aims to design and assess the impact of a differentiated CC screen and treat strategy in a district hospital; It will assess both its implementation and its effectiveness based on the completeness at each stage of the screening cascade. In addition, it will also include three sub-studies designed to evaluate :
- the performance of urinary HPV testing.
- the performance of different post-HPV test triage options (partial genotyping, simple or Artifical Intelligence assisted visual inspection, methylation markers)
- the risk of post-treatment cervical disease and the performance of different cure markers.
This will be a type 2 hybrid study that combines intervention research and implementation research. A quasi-experimental design ("before - after") combined with case study will be used for the effectiveness component of the research. During the first period, a single visit approach will be used while differentiated approach will be prepared using participatory research. During the second period, the differentiated approach will be implemented.
The general objective of this research is to assess the (cost-)effectiveness and implementation of different the two screening delivery strategies.
Main specific objectives include:
- To assess the effectiveness of each implementation strategy (in terms of cascade completeness)
- To assess the implementation of each strategy in terms of :
- Success through the measure of fidelity, reach and completeness
- Identification of adaptation, barriers and facilitating/leverage factors
- Perception, feasibility and acceptability of the screening strategies (by patients and health care workers)
- To assess the participants' stress levels during the screening process and to identify potential psychosocial support strategies
- To document the experience of WLHIV and health workers during the screening process and the post-treatment follow-up.
- To assess the performance of different triage methods among HPV+ participants (partial genotyping, simple or aided visual inspection, S5 methylation)
- To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples
- To assess the efficacy of thermal ablation treatment in terms of post-treatment cervical lesions
Methodology. The implementation research will combine quantitative and qualitative methods and will be based on the i-PARHIS model. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative. Biomedical data will be collected prospectively. The implementation data will combine routine monitoring data, cross-sectional surveys, interviews and observations. The analysis will be sequential or convergent depending on the stages of the project.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Quasi-experimental design ("before - after") combined with a case study
| Arm | Type | Receives |
|---|---|---|
| Single visit | Active comparator | Other: Single visitAll women will be screened using a single-visit approach |
| Differentiated prestation | Experimental | Other: Differentiated screening deliveryA more flexible screening approach will be offered based on the participants preference. After counseling (following the decision aid approach), participants may decide to performed the screening in two visits. |
Who may qualify
- Ages
- 25 to 49 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- HIV infection
- receiving antiretroviral therapy
- living in the department of the study hospital
Key exclusion criteria (8 listed)
- ongoing pregnancy
- hysterectomy
- treatment of cervical lesion in the past 12 months
- Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.);
- Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study Inclusion deferred if
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Differentiated screening deliveryMore flexibility in the screening delivery will be offered. A decision aid process will be implemented to help the participants deciding between the two options. | Other | Differentiated prestation |
| Single visitAll the steps of the screening (using HPV test) and of the treatment will be performed in a single visit (when possible). | Other | Single visit |
Primary outcome
Screening completeness
Time frame: 60 days post screening initiation
Proportion of HPV+ participants completing all screening steps within 60 days of inclusion.
5 secondary outcomes
Screening completeness 2
Time frame: 120 days post screening initiation
Acceptability of the screening delivery strategy
Time frame: Baseline (screening)
Triage performance
Time frame: Baseline (screening)
Performance of urinary HPV test
Time frame: Baseline (screeening)
Post treatment cervical lesion
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Cervical Cancer Screening
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Enrolling by invitationObservational study
Use of cfDNA in Monitoring and Guiding Treatment for Cervical Cancer
Cervical Cancer Screening
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
RecruitingObservational study
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Brain Cancer, Breast Cancer
Recruiting
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
Cervical Cancer, Kaposi Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pierre Debeaudrap, MD, PhD study director
Institut de Recherche pour le Développement (IRD)
Joëlle Sobngwi, MD, PhD principal investigator
RSD Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Differentiated screening delivery and Single visit in people with Cervical Cancer Screening and HIV, run by Institut de Recherche pour le Developpement at 1 site in Cameroon.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Cameroon. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andre-Pascal Goura, MD (+227679336464, cdpoptitri@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Screening completeness (time frame: 60 days post screening initiation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2025.